For U.S. Healthcare Professionals only
Patient Site
Indications

Indication

AUGTYRO^TM (repotrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
U.S. Full Prescribing Information
Patient Information
Patient Site

REQUEST A REP

ERROR 500

SORRY, SOMETHING WENT WRONG.

We're working on it.

This site is intended for U.S. Healthcare Professionals only.

AUGTYRO^TM and the related logo are trademarks of Turning Point Therapeutics, Inc.

3600-US-2400184 07/24

BACK TO TOP